Bottom Line: Patients with inflammatory bowel disease appeared more likely than patients without the disorder to develop Parkinson disease, while anti-tumor necrosis factor therapy for inflammatory bowel disease was associated with reduced incidence of Parkinson in a new study that analyzed administrative claims data for more than 170 million patients.
Why The Research Is Interesting: Inflammation is a potential biological trigger shared by both inflammatory bowel and Parkinson diseases. The role of reduced inflammation through anti-tumor necrosis factor therapy for Parkinson disease is mostly unknown.
Authors: Inga Peter, Ph.D., of the Ichan School of Medicine at Mount Sinai, New York, and coauthors
Study Design: This was an observational study. Researchers were not intervening for purposes of the study and they cannot control natural differences that could explain study findings.
Related Material: The editorial, "Discovering New Benefits From Old Drugs with Big Data - Promise for Parkinson Disease," by Clemens R. Scherzer, M.D., of Harvard Medical School and Brigham and Women's Hospital, Boston, and coauthors also is available on the For The Media website.
To Learn More: The full study is available on the For The Media website.
Editor's Note: The article contains conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.To place an electronic embedded link in your story: Links will be live at the embargo time: http://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2018.0605